Table 1.

Number of mutations and potential neoantigens in HCC patients included in the study

Patient	Mutations					Neoantigens
	Total MUT	Missense	No data base	RNA in T	No RNA in NT	Predicted HLA-I Binders*	Predicted HLA-II Binders*	Total Predicted Binders*
10 584	1217	350	263	16	15	7	3	10
10 594	1115	267	196	19	18	8	3	11
10 615	4018	1247	273	41	38	10	4	14
10 619	1112	276	196	21	21	12	7	19
10 622	984	270	190	26	22	13	4	17
10 627	1083	328	235	14	13	7	1	8
10 628	1218	296	200	10	9	6	1	7
10 632	1204	353	243	33	31	14	5	19
10 634	1103	274	205	–	–	–	–	–
10 635	1308	380	296	30	30	17	14	31
HLA063	5185	1409	1093	101	94	42	26	65
HLA066	4318	1061	819	60	42	26	9	35
HLA069	2862	735	544	40	34	20	7	27
HLA078	5118	1560	718	38	32	19	5	24
Median	1217.5	351.5	253	30	30	13	5	19

*Number of mutations originating peptides with in silico predicted capacity to bind to HLA class I or class II molecules.

HCC, hepatocellular carcinoma; NT, non-tumor.